Sinovac Biotech (北京科兴生物制品有限公司) has received an SFDA production license for Panflu.1, the company’s H1N1 vaccine. The SFDA approved the single-injection administration of the vaccine as sufficient to provide immunogenicity. As expected, the approval indicates the drug can be given to people from 3 to 60 years of age. The company's stock price remains very volatile. More details...

Stock Symbol: (NYSE Amex: SVA)